Li-Meng Yan or Yan Limeng, is a Chinese ophthalmologist and virologist. She claimed in interviews that she became aware of person-to-person transmission of COVID-19 in late December 2019, and that she attempted to communicate the risks to her superiors. She fled to the United States where she co-authored two preprint research papers.
About Li-Meng Yan in brief
Li-Meng Yan or Yan Limeng, is a Chinese ophthalmologist and virologist. She claimed in interviews that she became aware of person-to-person transmission of COVID-19 in late December 2019, and that she attempted to communicate the risks to her superiors. She fled to the United States where she co-authored two preprint research papers, published to the Zenodo platform on September 14 and October 8 respectively. The September 14 preprint said that SARS-CoV-2 had not emerged naturally in a \”spillover from animals\”, but had been produced in a laboratory. The October 8 preprint went further, saying that Sars-Cov-2 was a bioweapon created by laboratories under the control of the Chinese Communist Party. Yan’s hometown is Qingdao. Her research includes the study of The inhibition effect of propranolol on the corneal neovascularization in an alkali-induced injury mouse model and the challenges in developing a universal influenza vaccine. She earned a PhD in ophthalmology from Southern Medical University and sources differ on whether beforehand she received an MD degree or a master’s degree in ocularmology from Xiangya Medical College of Central South University. She alleges that the Chinese government and the World Health Organization knew about the person- to- person transmission of CoV-19 earlier than they reported or made public, and suppressed both her research and that of others. She also co- authored a three-paragraph-long paper entitled \”Viral dynamics in mild and severe cases of CO VID-19\” that was co-written by her now-former colleagues at HKU.
This paper did not undergo any peer-reviewed peer-review process, which did not mean that it was not peer reviewed. Yan’s co-authors were from HKU, including Leo Poon and Malik Peiris, and the remaining five were from the First Affiliated Hospital of Nanchang University. A co-author of the Nature Medicine article, University of Sydney biologist Edward Holmes, said that there was no evidence that the virus was manufactured in a lab. He said that all evidence points towards its origin in an animal species. The RaTG13 virus held in the Wuhan province of China came from a different province where COVID19 had first appeared from that where it was first discovered. There are no recorded viruses that could have been used as the backbone in the creation of SARS Virus 2 – this is equivalent to an average of 50 years of evolutionary change. The article gives several reasons why the virus is likely to have arisen naturally. It also says that the high nucleotide identity to SARS coronaviruses detected in horseshoe bats is similar to that of the SARS virus found in golden hamsters. The paper states that SATS-Co V-2 has a \”high nucleotide initiative to SARS – which does not appear to be the same as that found in humans.